Literature DB >> 15455230

c-KIT codon 816 mutation in a recurrent and metastatic dysgerminoma of a 14-year-old girl: case study.

Katharina Pauls1, Eva Wardelmann, Sabine Merkelbach-Bruse, Reinhard Büttner, Hui Zhou.   

Abstract

Dysgerminomas are rare female germ-cell tumors that correspond histologically and immunohistochemically to seminomas. Analogous to seminomas, most dysgerminomas respond very well to cisplatin- or carboplatin-based chemotherapy and to radiotherapy. KIT tyrosine kinase is crucial for normal germ-cell development, and its expression is observed in the majority of seminomas and dysgerminomas. Recently, activating KIT mutations were described in a panel of male germ-cell tumors [5, 10]. All mutations were localized in exon 17, encoding the second tyrosine kinase domain. Because receptor tyrosine kinase KIT might also be involved in the pathogenesis of dysgerminomas, we studied the expression and mutational status of a pure dysgerminoma, which was sent to our department for diagnostic reasons. The tumor revealed an exon 17 D816 V mutation in the c-KIT gene and strong KIT expression was found immunohistochemically. Clinically, the tumor was highly aggressive and resistant to carboplatin-based chemotherapy. Our case raises the question of whether exon 17 c-KIT mutations might be involved in the pathogenesis of dysgerminoma and whether exon 17 KIT mutations may predict aggressive and chemotherapy-resistant behavior of dysgerminomas.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15455230     DOI: 10.1007/s00428-004-1112-3

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  16 in total

1.  Angiotensin-converting enzyme (CD143) in neoplastic germ cells.

Authors:  K Pauls; L Fink; F E Franke
Journal:  Lab Invest       Date:  1999-11       Impact factor: 5.662

2.  c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia.

Authors:  M Gari; A Goodeve; G Wilson; P Winship; S Langabeer; D Linch; E Vandenberghe; I Peake; J Reilly
Journal:  Br J Haematol       Date:  1999-06       Impact factor: 6.998

3.  The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations.

Authors:  Yongsheng Ma; Shan Zeng; Dean D Metcalfe; Cem Akin; Sasa Dimitrijevic; Joseph H Butterfield; Gerald McMahon; B Jack Longley
Journal:  Blood       Date:  2002-03-01       Impact factor: 22.113

4.  c-kit mutations in gastrointestinal stromal tumors occur preferentially in the spindle rather than in the epithelioid cell variant.

Authors:  Eva Wardelmann; Iris Neidt; Erhard Bierhoff; Nicola Speidel; Christoph Manegold; Hans-Peter Fischer; Ulrich Pfeifer; Torsten Pietsch
Journal:  Mod Pathol       Date:  2002-02       Impact factor: 7.842

5.  A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib.

Authors:  Cem Akin; Gerard Fumo; Akif S Yavuz; Peter E Lipsky; Len Neckers; Dean D Metcalfe
Journal:  Blood       Date:  2003-12-24       Impact factor: 22.113

Review 6.  Current therapy for dysgerminoma of the ovary.

Authors:  G M Thomas; A J Dembo; N F Hacker; A D DePetrillo
Journal:  Obstet Gynecol       Date:  1987-08       Impact factor: 7.661

7.  KIT mutations are common in testicular seminomas.

Authors:  Kathleen Kemmer; Christopher L Corless; Jonathan A Fletcher; Laura McGreevey; Andrea Haley; Diana Griffith; Oscar W Cummings; Cecily Wait; Ajia Town; Michael C Heinrich
Journal:  Am J Pathol       Date:  2004-01       Impact factor: 4.307

8.  Flt-3 and c-kit mutation studies in a spectrum of chronic myeloid disorders including systemic mast cell disease.

Authors:  Animesh Pardanani; Terra L Reeder; Teresa K Kimlinger; Jin Y Baek; Chin-Y Li; Joseph H Butterfield; Ayalew Tefferi
Journal:  Leuk Res       Date:  2003-08       Impact factor: 3.156

9.  Stem cell factor protects germ cells from apoptosis in vitro.

Authors:  W Yan; J Suominen; J Toppari
Journal:  J Cell Sci       Date:  2000-01       Impact factor: 5.285

10.  Role of c-kit in mouse spermatogenesis: identification of spermatogonia as a specific site of c-kit expression and function.

Authors:  K Yoshinaga; S Nishikawa; M Ogawa; S Hayashi; T Kunisada; T Fujimoto; S Nishikawa
Journal:  Development       Date:  1991-10       Impact factor: 6.868

View more
  6 in total

1.  The D816V mutation of c-Kit circumvents a requirement for Src family kinases in c-Kit signal transduction.

Authors:  Jianmin Sun; Malin Pedersen; Lars Rönnstrand
Journal:  J Biol Chem       Date:  2009-03-05       Impact factor: 5.157

2.  Ovarian dysgerminomas are characterised by frequent KIT mutations and abundant expression of pluripotency markers.

Authors:  Christina E Hoei-Hansen; Sigrid M Kraggerud; Vera M Abeler; Janne Kaern; Ewa Rajpert-De Meyts; Ragnhild A Lothe
Journal:  Mol Cancer       Date:  2007-02-02       Impact factor: 27.401

Review 3.  Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells.

Authors:  Maryam Abbaspour Babaei; Behnam Kamalidehghan; Mohammad Saleem; Hasniza Zaman Huri; Fatemeh Ahmadipour
Journal:  Drug Des Devel Ther       Date:  2016-08-01       Impact factor: 4.162

4.  Assessing the Activation of Tyrosine Kinase KIT through Free Energy Calculations.

Authors:  Angélica Sandoval-Pérez; Beth Apsel Winger; Matthew P Jacobson
Journal:  J Chem Theory Comput       Date:  2022-09-27       Impact factor: 6.578

5.  Molecular abnormalities in ovarian cancer subtypes other than high-grade serous carcinoma.

Authors:  C Blake Gilks
Journal:  J Oncol       Date:  2009-12-30       Impact factor: 4.375

Review 6.  Molecular characteristics of malignant ovarian germ cell tumors and comparison with testicular counterparts: implications for pathogenesis.

Authors:  Sigrid Marie Kraggerud; Christina E Hoei-Hansen; Sharmini Alagaratnam; Rolf I Skotheim; Vera M Abeler; Ewa Rajpert-De Meyts; Ragnhild A Lothe
Journal:  Endocr Rev       Date:  2013-04-10       Impact factor: 19.871

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.